Intercept Pharmaceuticals (ICPT) Stock Analysis

What Intercept Pharmaceuticals does

Intercept Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in the advancement and market launch of therapies designed to treat progressive, non-viral liver conditions. Its operational reach spans the United States, Europe, and Canada. The company currently markets Ocaliva, a medication functioning as a farnesoid X receptor (FXR) agonist. This drug is approved for the treatment of primary biliary cholangitis (PBC) in adults, specifically when administered alongside ursodeoxycholic acid. Beyond its existing approved indications, Intercept is actively investigating Ocaliva's potential for additional uses, notably including nonalcoholic steatohepatitis (NASH). Concurrently, it is progressing other drug candidates through various clinical and preclinical stages of development. In a collaborative effort, the company holds a licensing agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. Intercept distributes its products through a dual approach, utilizing both its proprietary commercial organization and a network of external third-party distributors. The company was founded in 2002 and is headquartered in New York, New York.

Key metrics

ETFs linked to ICPT

Broad-market and Healthcare sector ETFs an investor holding Intercept Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ICPT fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Intercept Pharmaceuticals?

Intercept Pharmaceuticals trades under the ticker ICPT on NASDAQ.

Which exchange is ICPT listed on?

ICPT is listed on NASDAQ.

What sector does Intercept Pharmaceuticals operate in?

Intercept Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ICPT in a portfolio?

PortView shows ICPT's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.